The Effect of Empagliflozin Treatment on Epicardial Adipose Tissue and Cardiac Function in Patients With Type 2 Diabetes Mellitus
A diabetes drug reduces fat buildup around the heart and improves heart function in some patients, suggesting direct heart-protective effects beyond blood sugar control.
A prospective uncontrolled study in 75 T2DM patients showed empagliflozin reduced epicardial adipose tissue thickness and improved diastolic function parameters over 6 months. Findings are hypothesis-generating due to the single-arm design without a control group; EAT reduction did not correlate with individual metabolic marker changes, suggesting direct cardioprotective mechanisms.
What the study was
- Study design
- Prospective single-arm study (6-month follow-up, n=75)
- Population
- Adults with T2DM on stable oral antidiabetics, without established CVD
- Sample size
- 75
- Category
- Diagnostics
- Maturity
- Exploratory
- Journal
- Echocardiography
Why it surfaced
Prospective human data on SGLT2i cardiac mechanism (EAT thinning + diastolic improvement) in T2DM; single-arm without control; mechanistically informative but not practice-changing.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.